Neurxstem delivers the world’s first and most advanced synthetic mimic of the human central nervous system (CNS) in a dish. Dr. Rene Anand and Ms. Susan Mckay have developed a Neural Organoid Platform™ that is a novel, first in class system to study human brain disease mechanisms and to provide drug discovery, efficacy and safety testing.
Breakthrough stem cell technology has leap frogged over the research models of the past to the models of the future. While staggering sums of money have been spent on finding effective treatments for debilitating brain diseases, significant progress has remained elusive. Drugs that are effective in mice against a host of brain diseases including autism, Alzheimer’s disease, Parkinson’s disease or brain cancer tragically perform poorly in human patients, where it matters most.
With this incredible and powerful model system, no longer do we have to guess whether a treatment will be effective for a human brain disease based on other surrogate models. Neurxstem provides researchers and medical professionals with a human brain template to understand disease mechanisms and discover new treatments before advancing to clinical trials.
Dr. Rene Anand (Founder, CEO, Board of Directors)
Dr. Anand earned his BS (Chemistry) from Loyola College, India, M.S. (Chemistry/Chemical Physics) from the Indian Institute of Technology (IIT), Chennai, India, and his Ph.D. at The Ohio State University. His doctoral dissertation mentor was Dr. Elio Vanin, who trained with Dr. Oliver Smithies (U. Wisconsin), Nobel Prize winner, 2007. He did his postdoctoral training at the Salk Institute, San Diego and University of Pennsylvania, Philadelphia with Dr. Jon Lindstrom, Trustee Professor, and discoverer of cause of Myasthenia Gravis.
He held faculty positions at the University of Pennsylvania and Louisiana State University Neuroscience Center and is currently Professor in the Department of Biological Chemistry and Pharmacology at The Ohio State University College of Medicine and Wexner Medical Center. He has served on the grant review panel for Brain Canada, Alzheimer’s Association, NIH, Autism Speaks, California Tobacco-Related Disease Research Program (TRDRP), Hong Kong Research Grants Council, Israel Science Foundation, and American Association for Advancement of Science.
He has served on the External Scientific Advisory Board for the NERT program, Louisiana Tech, and on the NINDS Human DNA Repository, and Autism Speaks. Dr. Anand has earned the Lieber Independent Investigator Award from NARSAD as well as the Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) award from the National Institutes of Health for his research. His research has been funded by NIH, Autism Speaks, the Bill and Marci Ingram Family Fund, and the Brain and Behavior Foundation (NARSAD) and National Science Foundation.
Technology Marketing: Dr. Anand has been active in his role as CEO in marketing efforts at both domestic and foreign meetings with audiences that were both Pharma (World CNS Summit, Boston, Feb 2016) and academic technology first adopters (Cell press Aging and Metabolism, Sitges, Spain, July 2016; Cell press “10 years of iPSC”, Berkeley, Sept 2016; Society for Neuroscience meeting, Nov. 2016).
Client and customers recruitment: Academia - He has solicited and recruited beta clients who are enthusiastic about exploring the use of the technology to advance brain disease research and drug discovery. These include senior investigators at Yale Medical School – interested in Schizophrenia and multiple sclerosis, Cleveland Clinic – interested in Cancer, Autism and Tuberous sclerosis, Icahn Medical Center, Mt. Sinai - interested in Autism and U. Pennsylvania – interested in Sleep disorders. Pharma - He has communicated with investigators at Astra Zeneca, Boston, Eli Lilly, Indianapolis, Novartis, Boston and Abbvie to assess their needs in the CNS space. Private - He has communicated with senior scientific leaders of Simons Foundation and Autism Speaks to assess their goals and ways to address their scientific needs; Federal - Department of Defense. Neurxstem Inc’s technology is being explored to address the needs of veteran’s health, in particular Post Traumatic Stress Disorder. Dr. Anand has attended a meeting in Arlington, DC to work with MTEC , a new DoD private-public partnership to cater to the “Wounded Warrior” program.
Technology Commercialization: Neurxstem Inc will debut at a commercial booth at the Society for Neuroscience meeting 2016.
University Startup Demo Day Award: Neurxstem Inc. has been selected by the National Council of Entrepreneurial Tech Transfer (NCET2) event as one of the “Best University Startup 2016” companies to present to an audience of Fortune 500 companies and US Congress on September 20th in Washington DC.
Capital Acquisition: State of Ohio: Neurxstem Inc has been awarded a Technology Validation and Start-up Fund grant from the State of Ohio Third Frontier Fund for commercialization of its licensed technology. Private - A Venture Capital group and multiple other investors are in due diligence to invest in the company. Federal - A fast track Phase 1+2 STTR proposal to the National Institutes of Health is planned.
Ms. Susan McKay (CTO, Technology Co-Inventor, Board of Directors)
Susan McKay, MS, worked previously at the Ohio State University’s department of Pharmacology in the College of Medicine with 25 years of experience in clinical research in pharmacology, genetics and molecular biology. She holds BS from the University of Texas and an MS from the Medical College of Georgia and over 20 publications.
Dr. Manoj Malhotra (Senior Business Advisor; Board of Directors)
Dr. Malhotra has extensive business experience and his acumen critically guides Neurxstem Inc.’s business, financial and marketing decisions. He is a co-founder and serves on board of advisors for the management consulting firm Bigsky Associates since its inception in 2006. Details of the advisory board and founders can be seen at this site. A brief experience synopsis is included here.
Manoj K. Malhotra is the Jeff B. Bates Professor, and the Chair of the Management Science Department, since 2000 at the Darla Moore School of Business, University of South Carolina (USC), Columbia. He is also the founding Director of the Center for Global Supply Chain and Process Management (GSCPM). This Center has garnered over $3.5 Million in industry support since its inception in 2005 from firms such as Carolina Healthcare Systems, Coca Cola Bottling, Colonial, Ingersoll Rand, Johnson & Johnson, Michelin, Pfizer, Price Waterhouse Coopers, Siemens, and Textron among others. The academic excellence and research reputation of the Management Science department in the discipline has climbed steadily over the past 16 years, while its undergraduate program in Global Supply Chain and Operations Management (GSCOM) has recently been ranked 7th nationally, and the graduate program 15th nationally, by the Gartner Group. These programs produce graduates who receive placements at highly competitive salaries in well-regarded multinational firms and consulting organizations.
Dr. Malhotra earned an engineering undergraduate degree from the Indian Institute of Technology (IIT), Kanpur, India, in 1983, and a PhD in operations management from The Ohio State University in 1990. He is a Fellow of the Decision Sciences Institute (DSI) and the American Production and Inventory Management Society (APICS). Dr. Malhotra has conducted seminars, and consulted with and advised firms such as Avaya, Continental, Cummins Turbo Technologies, Delta Airlines, John Deere, Metso Paper, Nephron Pharmaceuticals, Palmetto Health, Sonoco, Prysmian, Verizon, Walmart, and Westinghouse-Toshiba.
Apart from teaching operations management, supply chain management, and global business issues at the Darla Moore School of Business, Dr. Malhotra has also taught at the Terry School of Business, University of Georgia; Wirtschaftsuniversität Wien in Austria; and the Graduate School of Management at Macquarie University, Australia. He is the co-author of a leading textbook in the field, which has been translated into several languages and is used around the globe. Dr. Malhotra’s research has thematically focused on the deployment of flexible resources in manufacturing and service firms, operations and supply chain strategy, and on the interface between operations management and other functional areas of business such as information systems and marketing. His work on these and related issues has been published in the leading refereed journals of the field such as Decision Sciences, European Journal of Operational Research, Interfaces, Journal of Operations Management, and Production and Operations Dr. Malhotra has been recognized for his pedagogical and scholarly contributions through several teaching and discipline-wide research awards. He is the recipient of the Michael J. Mungo Outstanding Graduate Teaching Award in 2006, the Carolina Trustee Professor Award in 2014, and the Breakthrough Leadership in Research Award in 2014 from the University of South Carolina. He is active in professional organizations such as Decision Sciences Institute (DSI) and Production and Operations Management Society (POMS), and has served as the program chair for international conferences at both DSI and POMS. He is currently the President-Elect of POMS. He also serves on the editorial boards of top-tier journals in the field, and is an active contributor to faculty governance activities at the University of South Carolina.
Dr. Johnny Rungtusanatham (Senior Business Advisor)
Dr. Rungtusanatham teaches courses related to operations excellence and has also been involved in program, university center, and non-profit business development in related fields. In 2003, he co-founded the online MBA degree offering at the WP Carey School of Business at Arizona State University with an initial budget of approximately $1.8 million, successfully leading efforts to develop courseware, articulate strategic positioning of the offering, market against other first movers, and grow a global enrollment base. He is currently advising and consulting with a 501c(3) non-profit (i) to stabilize its product and service offerings to members in order to revitalize its membership base and (ii) to establish new policies and technology-enabled procedures for efficient operations.
Professor Dame Pamela Shaw, MD, Director, SITraN, Sheffield, UK (Scientific Advisory Board)
Dr. David Pitt, MD, Professor, Yale, USA, Neurologist (Scientific Advisory Board)
David Pitt, MD, is a neurologist specializing in multiple sclerosis (MS) and other neuro-inflammatory diseases at Yale Medicine.
Dr. Pitt spends the majority of his time as a researcher, investigating the causes of neurodegeneration in MS. He is also working on a new imaging method to make inflammation visible in the brain so that doctors can adjust the way they treat MS at different stages of the disease. His research into the biological mechanisms behind MS informs his work as a physician.
When seeing patients, Dr. Pitt values taking the time to educate them about the nature of MS and how the scientific knowledge and treatments of the condition have substantially improved over the years. “The reputation of MS as a terrible disease lags behind how well we can treat it nowadays,” he says.
“I find it important to explain to newly diagnosed patients what it really means to have multiples sclerosis and how this might be different from their conception of what it is.”
In addition to treating patients and conducting research, Dr. Pitt is an associate professor of Neurology at the Yale School of Medicine.
Dr. Vinay Puduvalli, MD, Professor, OSU, USA, Director, Division of Neuro-Oncology (Scientific Advisory Board)
Dr. Peter Cruse, MD, Partner, Gulf Associates, Rhodes Scholar, Royal Society of Medicines , London, UK (Scientific Advisory Board)
Dr Peter Cruse is a former South African national medical Rhodes Scholar to Oxford University, Chief Specialist Pathologist at Groote Schuur Hospital in Cape Town, UCT Professor of Anatomical Pathology and MBA gold medallist. He is now an experienced commercial manager of multi-site hospitals, clinics and medical laboratories. He is a true “company doctor” capable of inspiring and leading rapid financial turnarounds of underperforming healthcare assets. His speciality is rapid performance enhancement. Focused on producing strongly positive EBITDA in excess of 20% by marketing-driven top-line revenue growth, Peter combines “hands on” charismatic leadership with surgically precise cost-cutting, lean methodology, productivity and efficiency gains. He rigorously uses data, dashboards, MIS, ICT and technology rather than simply employing more people to improve company performance.
As a UK-trained Specialist Histopathologist with an MBA and over thirty years of practical clinical and business management experience, the career of Dr Cruse has successfully combined clinical patient service with senior hospital, departmental and transformational business team leadership positions. He has led or worked in complex multi-site healthcare institutions in both the public and private sectors in five countries. He has extensive, full-time private equity experience of both investment fund raising and deal making. This has included simultaneous start-ups of multiple polyclinics, green-field new hospital builds as well as ongoing management of large multi-site healthcare organisations.